Guardado en:
Detalles Bibliográficos
Autores principales: João Lobo, Nuno Tiago Tavares, Fernanda Fernandes‐Pontes, Vera Constâncio, Ana Teixeira Marques, Bruno Oliveira‐Lopes, Diana Fonseca, Carmen Jerónimo, Rui Henrique, Kvetoslava Michalova, Kristine M Cornejo, Maurizio Colecchia, Costantino Ricci, Muhammad T Idrees, Felix Contreras, Isabel M Fernandez Gonzalez, William J Anderson, Fiona MacLean, Adeboye O Osunkoya, Chia‐Sui Kao, Ankur R Sangoi, Thomas M Ulbright, Andres M Acosta
Formato: Artículo Open Access
Publicado: Wiley 2025
Materias:
Acceso en línea:https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.6487
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
_version_ 1867019995996749824
author João Lobo
Nuno Tiago Tavares
Fernanda Fernandes‐Pontes
Vera Constâncio
Ana Teixeira Marques
Bruno Oliveira‐Lopes
Diana Fonseca
Carmen Jerónimo
Rui Henrique
Kvetoslava Michalova
Kristine M Cornejo
Maurizio Colecchia
Costantino Ricci
Muhammad T Idrees
Felix Contreras
Isabel M Fernandez Gonzalez
William J Anderson
Fiona MacLean
Adeboye O Osunkoya
Chia‐Sui Kao
Ankur R Sangoi
Thomas M Ulbright
Andres M Acosta
author_facet João Lobo
Nuno Tiago Tavares
Fernanda Fernandes‐Pontes
Vera Constâncio
Ana Teixeira Marques
Bruno Oliveira‐Lopes
Diana Fonseca
Carmen Jerónimo
Rui Henrique
Kvetoslava Michalova
Kristine M Cornejo
Maurizio Colecchia
Costantino Ricci
Muhammad T Idrees
Felix Contreras
Isabel M Fernandez Gonzalez
William J Anderson
Fiona MacLean
Adeboye O Osunkoya
Chia‐Sui Kao
Ankur R Sangoi
Thomas M Ulbright
Andres M Acosta
João Lobo
Nuno Tiago Tavares
Fernanda Fernandes‐Pontes
Vera Constâncio
Ana Teixeira Marques
Bruno Oliveira‐Lopes
Diana Fonseca
Carmen Jerónimo
Rui Henrique
Kvetoslava Michalova
Kristine M Cornejo
Maurizio Colecchia
Costantino Ricci
Muhammad T Idrees
Felix Contreras
Isabel M Fernandez Gonzalez
William J Anderson
Fiona MacLean
Adeboye O Osunkoya
Chia‐Sui Kao
Ankur R Sangoi
Thomas M Ulbright
Andres M Acosta
collection Wiley Open Access
contents MicroRNA profiling of testicular Leydig cell tumors identifies a microRNA signature associated with malignancy and miR ‐196b‐5p as a potentially useful biomarker João Lobo Nuno Tiago Tavares Fernanda Fernandes‐Pontes Vera Constâncio Ana Teixeira Marques Bruno Oliveira‐Lopes Diana Fonseca Carmen Jerónimo Rui Henrique Kvetoslava Michalova Kristine M Cornejo Maurizio Colecchia Costantino Ricci Muhammad T Idrees Felix Contreras Isabel M Fernandez Gonzalez William J Anderson Fiona MacLean Adeboye O Osunkoya Chia‐Sui Kao Ankur R Sangoi Thomas M Ulbright Andres M Acosta The Journal of Pathology Abstract Approximately 10% of testicular Leydig cell tumors (LCTs) are clinically malignant and unresponsive to systemic treatment. Predicting their clinical behavior can be problematic because there are no biomarkers that can consistently discriminate between benign and malignant LCTs. We assessed microRNA expression profiles of LCTs to identify differentially expressed microRNAs that could potentially distinguish benign from malignant neoplasms. The study consisted of two phases. In the first (discovery) phase, we interrogated 768 microRNAs in a series of 11 LCTs (six malignant and five benign) using Taqman Low‐Density Array (TLDA) microRNA profiling. In the second phase, we validated the top differentially expressed microRNA targets with real‐time quantitative PCR on a series of 35 LCTs (17 malignant and 18 benign), assessing their clinical performance for distinguishing malignant from benign LCTs. Target biologic pathways were analyzed using the miRTargetLink 2.0 tool. A total of 50 microRNAs were differentially regulated in malignant LCTs (27 upregulated, 23 downregulated). The top six microRNA candidates (top three upregulated and top three downregulated) were validated, showing good performance for discriminating between malignant and benign LCTs, with an area under the curve (AUC) ranging between 0.69 and 0.87. MiR‐196b‐5p showed the best performance, with sensitivity, specificity, negative predictive value, positive predictive value, and accuracy of 82%, 83%, 83%, 82%, and 83%, respectively. A panel (i.e. combined) analysis reached 100% sensitivity and 83% specificity. Pathway analysis revealed significant overlap in the biological process targeted by the upregulated microRNAs in malignant LCTs, including proliferation, development, metabolism, hormone synthesis, and cell death. Our results support the idea that malignant LCTs are associated with a distinct microRNA signature. MiR‐196b‐5p was identified as a potentially useful biomarker to distinguish benign from malignant tumors. The shared downstream targets of the top upregulated microRNAs suggest that dysregulation of cell proliferation and apoptosis underlie aggressive biologic behavior in LCTs and may offer opportunities for targeted therapies. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. 10.1002/path.6487 http://creativecommons.org/licenses/by/4.0/
doi_str_mv 10.1002/path.6487
format Artículo Open Access
id wiley_oa_10_1002_path_6487
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by/4.0/
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle MicroRNA profiling of testicular Leydig cell tumors identifies a microRNA signature associated with malignancy and miR ‐196b‐5p as a potentially useful biomarker
João Lobo
Nuno Tiago Tavares
Fernanda Fernandes‐Pontes
Vera Constâncio
Ana Teixeira Marques
Bruno Oliveira‐Lopes
Diana Fonseca
Carmen Jerónimo
Rui Henrique
Kvetoslava Michalova
Kristine M Cornejo
Maurizio Colecchia
Costantino Ricci
Muhammad T Idrees
Felix Contreras
Isabel M Fernandez Gonzalez
William J Anderson
Fiona MacLean
Adeboye O Osunkoya
Chia‐Sui Kao
Ankur R Sangoi
Thomas M Ulbright
Andres M Acosta
The Journal of Pathology
MicroRNA profiling of testicular Leydig cell tumors identifies a microRNA signature associated with malignancy and miR ‐196b‐5p as a potentially useful biomarker João Lobo Nuno Tiago Tavares Fernanda Fernandes‐Pontes Vera Constâncio Ana Teixeira Marques Bruno Oliveira‐Lopes Diana Fonseca Carmen Jerónimo Rui Henrique Kvetoslava Michalova Kristine M Cornejo Maurizio Colecchia Costantino Ricci Muhammad T Idrees Felix Contreras Isabel M Fernandez Gonzalez William J Anderson Fiona MacLean Adeboye O Osunkoya Chia‐Sui Kao Ankur R Sangoi Thomas M Ulbright Andres M Acosta The Journal of Pathology Abstract Approximately 10% of testicular Leydig cell tumors (LCTs) are clinically malignant and unresponsive to systemic treatment. Predicting their clinical behavior can be problematic because there are no biomarkers that can consistently discriminate between benign and malignant LCTs. We assessed microRNA expression profiles of LCTs to identify differentially expressed microRNAs that could potentially distinguish benign from malignant neoplasms. The study consisted of two phases. In the first (discovery) phase, we interrogated 768 microRNAs in a series of 11 LCTs (six malignant and five benign) using Taqman Low‐Density Array (TLDA) microRNA profiling. In the second phase, we validated the top differentially expressed microRNA targets with real‐time quantitative PCR on a series of 35 LCTs (17 malignant and 18 benign), assessing their clinical performance for distinguishing malignant from benign LCTs. Target biologic pathways were analyzed using the miRTargetLink 2.0 tool. A total of 50 microRNAs were differentially regulated in malignant LCTs (27 upregulated, 23 downregulated). The top six microRNA candidates (top three upregulated and top three downregulated) were validated, showing good performance for discriminating between malignant and benign LCTs, with an area under the curve (AUC) ranging between 0.69 and 0.87. MiR‐196b‐5p showed the best performance, with sensitivity, specificity, negative predictive value, positive predictive value, and accuracy of 82%, 83%, 83%, 82%, and 83%, respectively. A panel (i.e. combined) analysis reached 100% sensitivity and 83% specificity. Pathway analysis revealed significant overlap in the biological process targeted by the upregulated microRNAs in malignant LCTs, including proliferation, development, metabolism, hormone synthesis, and cell death. Our results support the idea that malignant LCTs are associated with a distinct microRNA signature. MiR‐196b‐5p was identified as a potentially useful biomarker to distinguish benign from malignant tumors. The shared downstream targets of the top upregulated microRNAs suggest that dysregulation of cell proliferation and apoptosis underlie aggressive biologic behavior in LCTs and may offer opportunities for targeted therapies. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. 10.1002/path.6487 http://creativecommons.org/licenses/by/4.0/
title MicroRNA profiling of testicular Leydig cell tumors identifies a microRNA signature associated with malignancy and miR ‐196b‐5p as a potentially useful biomarker
topic The Journal of Pathology
url https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.6487